Activated interferon response from DNA damage in multiple myeloma cells contributes to the chemotherapeutic effects of anthracyclines

被引:1
|
作者
Li, Jin [1 ]
Jia, Zhuxia [1 ]
Wang, Rongxuan [1 ]
Xiao, Bitao [1 ]
Cai, Yanan [1 ]
Zhu, Tianshu [1 ]
Wang, Weiya [1 ]
Zhang, Xinyue [1 ]
Fan, Shu [1 ]
Fan, Xiaolong [2 ]
Han, Wenmin [1 ]
Lu, Xuzhang [1 ]
机构
[1] Nanjing Med Univ, Changzhou 2 Peoples Hosp, Affiliated Hosp, Dept Hematol, Changzhou, Peoples R China
[2] Beijing Normal Univ, Beijing Key Lab Gene Resource & Mol Dev, Lab Neurosci & Brain Dev, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
multiple myeloma; DNA damage response; doxorubicin; drug resistance; type 1 interferon (IFN-I); GAMMA-H2AX; ALPHA; RADIATION; MARKER;
D O I
10.3389/fonc.2024.1357996
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells in bone marrow. Upfront identification of tumor subgroups with specific biological markers has the potential to improve biologically-driven therapy. Previously, we established a molecular classification by stratifying multiple myeloma into two subtypes with a different prognosis based on a gene module co-expressed with MCL-1 (MCL1-M).Methods Gene Ontology (GO) analysis with differentially expressed genes was performed to identify signal pathway. Drug sensitivity was analyzed using the OncoPredict algorithm. Drug sensitivity of different myeloma cell lines was detected by CCK8 and flow cytometry. RNA-seq was performed on drug-sensitive cell lines before and after adriamycin treatment. RT-qPCR was used to further verify the sequencing results. The expression of gamma-H2AX and dsDNA in sensitive and resistant cell lines was detected by immunofluorescence method.Results In our study, we demonstrated that MCL1-M low MM were more sensitive to anthracyclines. We treated different myeloma cell lines with doxorubicin in vitro and discovered the association of drug sensitivity with IFN signaling. Herein, we demonstrate that the doxorubicin-sensitive myeloma cell line showed significant DNA damage and up-regulated expression of genes related to the IFN response, which was not observed in drug-insensitive cell lines.Discussion Our results suggest that the active IFN signaling pathway may serve as a marker for predicting chemotherapy sensitivity in patients with myeloma. With our MCL1-M molecular classification system, we can screen patients with a potentially good response to the interferon signaling pathway and provide individualized treatment for MM. We propose IFN-a as adjuvant therapy for patients with myeloma sensitive to anthracyclines to further improve the therapeutic effect and prolong the survival of patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Inhibition of FEN1 promotes DNA damage and enhances chemotherapeutic response in prostate cancer cells
    Wang, Zhouyuan
    Yong, Chenxuan
    Fu, Yulian
    Sun, Yuling
    Guo, Zhigang
    Liu, Song-Bai
    Hu, Zhigang
    MEDICAL ONCOLOGY, 2023, 40 (08)
  • [32] COMPROMISED ACTIVITY OF NUCLEAR SIRTUINS SENSITIZES BRCANESS MULTIPLE MYELOMA CELLS TO DNA DAMAGE AGENTS
    Cagnetta, A.
    Cea, M.
    Munshi, A.
    Tai, Y. T.
    Hideshima, T.
    Chauhan, D.
    Roccaro, A.
    Nencioni, A.
    Patrone, F.
    Munshi, N.
    Anderson, K.
    HAEMATOLOGICA, 2012, 97 : 225 - 225
  • [33] A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells
    Ray, Arghya
    Ravillah, Durgadevi
    Das, Deepika S.
    Song, Yan
    Nordstrom, Eva
    Gullbo, Joachim
    Richardson, Paul G.
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (03) : 397 - 409
  • [34] PRODUCTION OF INTERFERON BY MALIGNANT PLASMA-CELLS FROM PATIENTS WITH MULTIPLE-MYELOMA
    EPSTEIN, LB
    SALMON, SE
    JOURNAL OF IMMUNOLOGY, 1974, 112 (03): : 1131 - 1138
  • [35] JS']JS-K, a GST-activated nitric oxide generator, induces DNA double strand breaks, activates DNA damage response pathways and induces apoptosis in human multiple myeloma cells
    Kiziltepe, Tanyel
    Hideshima, Teru
    Ishitsuka, Kenji
    Raje, Noopur
    Li, Chun-Qi
    Trudel, Laura J.
    Yasui, Hiroshi
    Catley, Laurence
    Ocio, Enrique M.
    Tai, Yu-Tzu
    Chauhan, Dharminder
    Saavedra, Joseph E.
    Wogan, Gerald N.
    Keefer, Larry K.
    Shami, Paul J.
    Anderson, Kenneth C.
    CANCER RESEARCH, 2006, 66 (08)
  • [36] An Inverse Switch in DNA Base Excision and Strand Break Repair Contributes to Melphalan Resistance in Multiple Myeloma Cells
    Sousa, Mirta M. L.
    Zub, Kamila Anna
    Aas, Per Arne
    Hanssen-Bauer, Audun
    Demirovic, Aida
    Sarno, Antonio
    Tian, Erming
    Liabakk, Nina B.
    Slupphaug, Geir
    PLOS ONE, 2013, 8 (02):
  • [37] AURKA Regulates the Mechanism of ATR Mediated DNA Damage Response about Drug Resistance in Multiple Myeloma
    Zhang Shuaishuai
    Qin, Yu
    Gang, An
    Hao, Mu
    Xu, Yan
    Deng, Shuhui
    Yu, Tengteng
    Zhou, Wen
    Qiu, Lugui
    BLOOD, 2017, 130
  • [38] Effects of interferon-α-2a on Th3 cytokine response in multiple myeloma patients
    Sonmez, M
    Sonmez, B
    Eren, N
    Yilmaz, M
    Karti, SS
    Ovali, E
    TUMORI JOURNAL, 2004, 90 (04): : 387 - 389
  • [39] ELEVATED 2-OXOGLUTARATE ANTAGONIZES CHEMOTHERAPEUTIC EFFECTS IN CHOLANGIOCARCINOMA BY TARGETING DNA DAMAGE RESPONSE SIGNALING PATHWAYS
    Nagaoka, Katsuya
    Ji, Chengcheng
    Bai, Xuewei
    Cao, Kevin
    Mulla, Joud
    Bay, Amalia
    Mueller, William
    Hildebrand, Grace
    Tanaka, Yasuhito
    Wands, Jack R.
    Huang, Chiung-Kuei
    HEPATOLOGY, 2021, 74 : 687A - 688A
  • [40] Lack of DNA Damage Response at Low Radiation Doses in Adult Stem Cells Contributes to Organ Dysfunction
    Nagle, Peter W.
    Hosper, Nynke A.
    Barazzuol, Lara
    Jellema, Anne L.
    Baanstra, Mirjam
    van Goethem, Marc-Jan
    Brandenburg, Sytze
    Giesen, Ulrich
    Langendijk, Johannes A.
    van Luijk, Peter
    Coppes, Rob P.
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6583 - 6593